Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Neoplasm Metastasis 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Imatinib Mesylate 71Sunitinib 31regorafenib 17nilotinib 15ripretinib 13avapritinib 7Laparoscopy 5Ipilimumab 5Dasatinib 5spartalizumab 4CTLA-4 Antigen 4Blood Specimen Collection 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Oxaliplatin 3Observation 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Biopsy 3Bevacizumab 3trametinib 2tanespimycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × masitinib × Gastrointestinal × Clear all
NCT00812240 2023-02-01

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

AB Science

Phase 3 Terminated
335 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT01694277 2020-12-08

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

AB Science

Phase 3 Completed
258 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡